You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
|
|---|---|
| Published in |
Molecular Cancer, December 2014
|
| DOI | 10.1186/1476-4598-13-259 |
| Pubmed ID | |
| Authors |
Venkatasubbaiah A Venkatesha, Asavari Joshi, Magesh Venkataraman, Vinay Sonawane, Dimple Bhatia, Prashant Tannu, Julie Bose, Sarika Choudhari, Ankita Srivastava, Prashant Kumar Pandey, Vaibhavi J Lad, Ramachandra Sangana, Tausif Ahmed, Anagha Damre, Vijaykumar Deore, Bichismita Sahu, Sanjay Kumar, Somesh Sharma, Veena R Agarwal |
| Abstract |
Lung cancer is the major cause of cancer-related deaths and many cases of Non Small Cell Lung Cancer (NSCLC), a common type of lung cancer, have frequent genetic/oncogenic activation of EGFR, KRAS, PIK3CA, BRAF, and others that drive tumor growth. Some patients though initially respond, but later develop resistance to erlotinib/gefitinib with no option except for cytotoxic therapy. Therefore, development of novel targeted therapeutics is imperative to provide improved survival benefit for NSCLC patients. The mTOR cell survival pathway is activated in naïve, or in response to targeted therapies in NSCLC. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 21% |
| Researcher | 5 | 21% |
| Student > Bachelor | 3 | 13% |
| Student > Master | 2 | 8% |
| Unspecified | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 21% |
| Medicine and Dentistry | 4 | 17% |
| Agricultural and Biological Sciences | 3 | 13% |
| Unspecified | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 7 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2022.
All research outputs
#7,428,992
of 22,711,242 outputs
Outputs from Molecular Cancer
#543
of 1,716 outputs
Outputs of similar age
#107,756
of 361,100 outputs
Outputs of similar age from Molecular Cancer
#11
of 32 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,716 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,100 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.